LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Interview with… Agne Vaitkeviciene, Executive Director of LBTA

28/04/2021
INTERVIEW

About Agne Vaitkeviciene

Agne Vaitkeviciene holds a BS in molecular biology (Vilnius University, Lithuania) and MS in organ, tissue and cell donation (University of Barcelona, Spain). Since 2006 she has been working in the field of cell therapy. In 2013 Agne Vaitkeviciene co-founded a life science start-up company and managed its activities in the field of advanced therapy medicinal product research and manufacturing as CEO until 2019.

Since 2019 she is actively involved as an expert in EU programs, such as IMI2, EIT Health Innostars and consults biotechnology companies in life science product development management. For the last 3 years Agne Vaitkeviciene has been actively involved in life science expert groups within governmental organizations such as “Enterprise Lithuania”, Science, Innovation and Technology Agency, “Invest Lithuania” and others. Lithuanian biotechnology association elected Agne as a vice-president in 2019 and delegated responsibilities of coordinating foreign affairs and startup support activities within the association. In 2020 Agne Vaitkeviciene became an executive director of Lithuanian biotechnology association. Agne is a board member at Vilnius University Life Science Center and Center of Innovative Medicine. From 2021 February Agne joined US based company Cureline Group Inc., as a Chief Operating Officer to run the branch "Cureline Baltic" in Vilnius, Lithuania.

Interview with... Agne Vaitkeviciene, Vice-President of the Lithuanian Biotechnology Association (LBTA)

1) What inspired the foundation of LBTA?
Since the foundation of the Lithuanian Biotechnology Association in 2003, the association had one main objective: to unite and bring together experts from the country's biotechnology sector. To this day, we aim to foster this idea, while actively striving to involve as many profound biotechnology professionals from business and academia, as well as actively communicating about the ever-changing and growing sector with the society.

2) What are the priorities of your members in Lithuania?
Lithuanian biotechnology association focus on three priority areas covering life sciences, health technologies and bioeconomy. Our members consist of academia, SMEs and corporations operating in the field of biotechnology. We believe that fostering stronger academia-business collaboration and supporting start-up ecosystem acceleration processes, as well as enabling regulatory flexibility for technological implementation are the key priority tasks for our members.

3) How does Lithuania want to position itself within the European biotech economy?
Lithuania’s life science sector is one of the fastest growing in Europe. The contribution of the biotechnology industry to Lithuania’s GDP grew from 0.82% in 2010 and to 2.38% in 2019. In 2020, during the pandemic, sector’s revenue has increased by about 1.5 times and preliminary data shows, that it will be reaching 3.5% of Lithuania’s GDP. Our sector has repeatedly demonstrated the impact on the global biotech arena, starting from Lithuanian-based companies like Thermo fisher Scientific, to the development of niche technologies in universities or start-ups. Globally leading technologies are focused in the field of gene engineering, biomolecule synthesis, synthetic biology and omic technologies. Following the direction of EU Green Deal, Lithuania’s biotechnology sector emphasises its contribution within biotechnology-based bioeconomy seeking to build strong collaborative initiatives.

4) What partnerships are you looking to achieve in EuropaBio?
We are seeking to support academia and biotech industry in Lithuania to become a significant part of Europe biotechnology progress and growth. Therefore, we are open for collaborative projects, acceleration indicatives, international partnerships. We believe that Lithuania, as well as other Baltic states, are unintentionally overlooked and could become strong force for Europe’s goals of the future.

Download the full INTERVIEW below.

Interview with Lithuanian Biotechnology Association


Download
2021_04_G_O_Interview-with…-LBTADownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
10/04/2025

EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.